ArticleFrontiers in oncology2020
Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Multi-Omics Analysis IdentifiedInternational journal of molecular sciences · 2026Article
- Machine learning-driven multi-targeted drug discovery in colon cancer using biomarker signatures.NPJ precision oncology · 2025Article
- Integrated spatial and single cell transcriptomics identifies PRKDC as a dual prognostic biomarker and therapeutic target in hepatocellular carcinoma.Scientific reports · 2025Article
- Investigation of high-mobility group box 1 variants with lymph node status and colorectal cancer risk.World journal of gastrointestinal oncology · 2025Article
- Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis.Scientific reports · 2025Article
- Selection of optimal extraction and RT-PCR protocols for stool RNA detection of colorectal cancer associated immune genes.Scientific reports · 2024Article
- Leukotriene B4 receptor knockdown affects PI3K/AKT/mTOR signaling and apoptotic responses in colorectal cancer.Biomolecules & biomedicine · 2024Article
- One-Step Automatic Radiosynthesis and Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Identification of the potential regulatory interactions in rheumatoid arthritis through a comprehensive analysis of lncRNA-related ceRNA networks.BMC musculoskeletal disorders · 2023Article
- Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group as PotentialPharmaceuticals (Basel, Switzerland) · 2023Review
- The dynamic dysregulated network identifies stage-specific markers during lung adenocarcinoma malignant progression and metastasis.Molecular therapy. Nucleic acids · 2022Article
- Novel six-gene prognostic signature based on colon adenocarcinoma immune-related genes.BMC bioinformatics · 2022Article
- Article
- Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients.Medicine · 2022Article
- Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.Frontiers in immunology · 2022Article
- HAMP as a Prognostic Biomarker for Colorectal Cancer Based on Tumor Microenvironment Analysis.Frontiers in oncology · 2022Article
- A Prognostic Model Using Immune-Related Genes for Colorectal Cancer.Frontiers in cell and developmental biology · 2022Article
- Article
- Identification of Circular RNA-Based Immunomodulatory Networks in Colorectal Cancer.Frontiers in oncology · 2021Article
- Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe immunosuppressive microenvironment is closely related to tumorigenesis and cancer development, including colorectal cancer (CRC). The aim of the current study was to identify new immune biomarkers for the diagnosis and treatment of CRC. MATERIALS AND
methodsCRC data were downloaded from the Gene Expression Omnibus and The Cancer Genome Atlas databases. Sequences of immune-related genes (IRGs) were obtained from the ImmPort and InnateDB databases. Gene set enrichment analysis (GSEA) and transcription factor regulation analysis were used to explore potential mechanisms. An immune-related classifier for CRC prognosis was conducted using weighted gene co-expression network analysis (WGCNA), Cox regression analysis, and least absolute shrinkage and selection operator (LASSO) analysis. ESTIMATE and CIBERSORT algorithms were used to explore the tumor microenvironment and immune infiltration in the high-risk CRC group and the low-risk CRC group.
resultsBy analyzing the IRGs that were significantly associated with CRC in the module, a set of 13 genes (CXCL1, F2RL1, LTB4R, GPR44, ANGPTL5, BMP5, RETNLB, MC1R, PPARGC1A, PRKDC, CEBPB, SYP, and GAB1) related to the prognosis of CRC were identified. An IRG-based prognostic signature that can be used as an independent potentially prognostic indicator was generated. The ROC curve analysis showed acceptable discrimination with AUCs of 0.68, 0.68, and 0.74 at 1-, 3-, and 5- year follow-up respectively. The predictive performance was validated in the train set. The potential mechanisms and functions of prognostic IRGs were analyzed, i.e., NOD-like receptor signaling, and transforming growth factor beta (TGFβ) signaling. Besides, the stromal score and immune score were significantly different in high-risk group and low-risk group (p=4.6982e-07, p=0.0107). Besides, the proportions of resting memory CD4
conclusionsThe IRG-based classifier exhibited strong predictive capacity with regard to CRC. The survival difference between the high-risk and low-risk groups was associated with tumor microenvironment and immune infiltration of CRC. Innovative biomarkers for the prediction of CRC prognosis and response to immunological therapy were identified in the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.